Leerink Partnrs Has Bearish Estimate for DNLI Q4 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for Denali Therapeutics in a report released on Tuesday, August 12th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($0.82) per share for the quarter, down from their prior forecast of ($0.80). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. Leerink Partnrs also issued estimates for Denali Therapeutics’ FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at $0.55 EPS and FY2029 earnings at $0.70 EPS.

Several other equities analysts also recently commented on the stock. Robert W. Baird decreased their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Bank of America decreased their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. William Blair upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Wedbush reduced their price target on Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $33.85.

Denali Therapeutics Stock Up 1.7%

DNLI stock opened at $14.70 on Friday. Denali Therapeutics has a fifty-two week low of $10.57 and a fifty-two week high of $33.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 9.56. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -5.25 and a beta of 1.36. The business’s fifty day moving average price is $14.30 and its two-hundred day moving average price is $15.31.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same period last year, the firm earned ($0.59) EPS.

Insider Buying and Selling

In other news, insider Carole Ho sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider owned 217,391 shares of the company’s stock, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider owned 242,346 shares in the company, valued at approximately $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock worth $7,520,799 in the last ninety days. 12.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its holdings in shares of Denali Therapeutics by 339.6% during the first quarter. SG Americas Securities LLC now owns 48,365 shares of the company’s stock worth $658,000 after buying an additional 37,362 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Denali Therapeutics by 4.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 85,075 shares of the company’s stock worth $1,733,000 after acquiring an additional 3,411 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Denali Therapeutics in the 1st quarter worth about $254,000. GAMMA Investing LLC raised its position in Denali Therapeutics by 253.8% in the first quarter. GAMMA Investing LLC now owns 7,953 shares of the company’s stock valued at $108,000 after purchasing an additional 5,705 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Denali Therapeutics by 260.9% during the fourth quarter. First Trust Advisors LP now owns 65,442 shares of the company’s stock valued at $1,334,000 after purchasing an additional 47,308 shares in the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.